Canaccord analyst William Maughan raised the firm’s price target on BioNTech (BNTX) to $171.44 from $171 and keeps a Buy rating on the shares. The firm said there are no checkpoint inhibitors currently approved for PD-L1 low and negative groups and they see this as a great strategic path towards potential accelerated approval in the indication as well as a means of gaining an edge on ‘327’s competitors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target lowered to $122 from $124 at JPMorgan
- Trump Trade: Trump Media considers developing crypto payment service
- Trump expected to pick Martin Makary to head FDA, Reuters reports
- Walmart higher, Lowe’s lower after earnings: Morning Buzz
- Workday initiated, Kraft Heinz downgraded: Wall Street’s top analyst calls